Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

The neurosteroids sulphate PREGS and DHEAS exert a facilitative role on learning performance in adult male rats

Neurosteroid PREGS differently affects learning and memory performance by altering emotionality in a gender-related manner

Disturbi del comportamento alimentare in età pre-scolare: variabili cliniche e temperamentali.

Disturbi del comportamento alimentare in età-prescolare: variabili cliniche e temperali.